DoW Multiple Sclerosis Clinical Trial Award
Supports preliminary or early-phase clinical trials in multiple sclerosis for organizations eligible to apply, to test new drugs, biologics, devices, clinical guidance, or emerging technologies aligned to FY26 MSRP focus areas.
⚑ Must address at least one FY26 MSRP Clinical Trial Award focus area. · Preliminary data in MS-relevant populations or for the proposed clinical trial are required. · Two funding levels: FL1 small proof-of-principle/pilot/first-in-human/phase 0; FL2 larger phase 1 or 2 trials. · Direct clinical trial award; not a basic research mechanism.
Unit fits — one characterization, each unit's own rules
| IPPRA | 58 good | portfolio topic: public_health; social/behavioral work is minor; funds evaluation research; clinical-trial/biomedical core — IPPRA angle is policy/community (capped) |
| Physical Sciences & Engineering (demo) | 50 partial | technical depth: substantial; funds evaluation research (capped) |
| Tom Love Innovation Hub | 30 weak | prototyping/demonstration stage; deep-tech content |
Description
Summary: The fiscal year 2026 (FY26) Multiple Sclerosis Research Program (MSRP) Clinical Trial Award (CTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of multiple sclerosis. All applications must address at least one of the FY26 MSRP CTA focus areas. Clinical trials may evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance and/or emerging approaches and technologies.
Distinctive Features: The FY26 CTA offers two funding levels. The following are generalized descriptions of the scope of research appropriate for each funding level:
• Funding Level 1 (CTA-FL1) supports small-scale, proof-of-principle clinical trials (e.g., pilot, first-in-human, phase 0) to demonstrate feasibility or inform the design of more advanced trials, or other clinical trials that are appropriate for this funding level. Preliminary data relevant to the proposed clinical trial are required.
• Funding Level 2 (CTA-FL2) supports larger-scale clinical trials at phase 1 or phase 2 that seek to show preliminary evidence of safety or efficacy (i.e., benefit of clinical or paraclinical outcomes) in relevant patient populations. Clear description and justification should be provided, which could include, but is not limited to, the intervention type, trial duration, sample size, outcome measures, assessment tools and frequency of assessment. Preliminary data relevant to the proposed clinical trial in MS populations are required.
For the purposes of this funding opportunity, Regulatory Agency refers to the U.S. Food and Drug Administration (FDA) or any relevant international regulatory agency unless otherwise noted.
Apply
View on Grants.gov → CONTACT: JoAnn Martin Grantor <help@eBRAP.org>